Liver Metastases Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy), By Primary Cancer (Colorectal, Breast), By Distribution Channel, By Region, and Segment Forecasts, 2023 - 2030

Report Overview

The global liver metastases treatment market size was valued at USD 1.32 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 7.2% from 2023 to 2030. This can be attributed to the rising incidence of the target disease. According to the National Library of Medicine, approximately 5.14% of total cancer cases were diagnosed with synchronous metastatic hepatocellular cancer in 2020. Breast cancer and colorectal cancer are the most common sites for liver metastases in young women and men. The rising number of cases is thus expected to boost demand for drugs over the forecast period. Moreover, growing research in the field positively contributes to market growth. Several government and non-profit organizations are actively involved in research activities. For instance, the National Cancer Institute is running a program P01 focusing on understanding the common mechanism involved in the development of liver metastases using disparate tumor models. Successful completion of the study is expected to boost the development of novel diagnostics and medicines for treatment in the coming years.

然而,缺乏适当的diagno的可用性stic and treatment methods for liver metastases is expected to slow down the market growth worldwide. Currently, the diagnosis of colorectal cancer liver metastases is performed with help of focal biopsy and imaging examinations but the lack of sensitivity in imaging diagnosis of hepatocellular carcinoma consequently restrains the market growth. Therefore, it is necessary to develop appropriate and novel methods for diagnostics.

Radiation therapy, ablation treatments, and surgery are some of the most commonly used treatments for metastasized hepatocellular carcinoma. The availability and wide usage of these treatments are expected to restrain the market growth of the liver metastases treatment drugs market.

Treatment Type Insights

The chemotherapy segment accounted for a revenue share of 39.30% in 2022. This can be attributed to their high usage rate in the past years owing to the increasing incidence of primary cancers that are responsible for liver metastases in patients. Systemic chemotherapy is mostly used in patients with unresectable hepatocellular carcinoma due to prolonged survival time compared to other treatment methodologies. Several research studies demonstrated that the use of oxaliplatin in combination with fluorouracil and calcium folinate increases the rate of survival in CRLM patients. However, side effects such as a liver injury due to the prolonged use of systemic chemotherapy may impede the market growth.

The targeted therapy segment is expected to witness lucrative growth over the forecast period owing to the wide availability of molecular targeted therapy drugs and emergence as an effective alternative medicine over other treatment methodologies. Some of the key molecular targeted therapy drugs used are Cetuximab, Panizumab, and Bevacizumab. Among them, Cetuximab and Panizumab are the most used drugs. Cetuximab is used as first-line drug therapy in patients with CCLM Thus, the growing use of targeted therapy medicines to treat patients with CRLM is projected to drive market growth.

Primary Cancer Insights

The colorectal cancer segment dominated the market with a revenue share of 40.55% in 2022. This dominance can be attributed to the increasing number of new cases of colorectal liver metastases. The liver is the main site for distant metastasis in the male population with colorectal cancer. As per a study published, in January 2021, around 1.4 million new cases of colorectal cases were diagnosed worldwide. Some research studies suggest that around 25-30% of patients with colorectal cancer develop liver metastases. Hence, the early diagnosis and treatment of colorectal cancer are most important to reduce the disease burden.

The breast cancer segment is expected to grow at a high growth rate over the forecast period. Women with metastatic breast cancer are more prone to develop liver metastases. According to Breastcancer.org, nearly 50% of the population diagnosed with breast cancer develop liver metastases. Other key cancers that metastasize to the liver include the bladder, kidney, and lung.

Distribution Channel Segment Insights

The hospital pharmacy segment dominated the market with a revenue share of 43.86% in 2022. The dominance of this segment can be attributed to the high hospitalization rate of patients suffering from liver metastases. Additionally, chemotherapy is generally administered in combination with radiation therapy, which is administered in hospitals, which further contributes to the segment’s dominance.

Specialty pharmacies are a key component in the distribution of oncology drugs. Specialty pharmacists have experience in dealing with products that have special handling requirements, and complex dosing schedules, hence are used as a major distribution medium for oncology drugs.

Regional Insights

North America dominated the global market in terms of the revenue share of 40.89% in 2022. The favorable reimbursement policies for stage 4 cancers and the availability of advanced treatment options improve access to treatment. There are around 140,000 people with liver metastases annually in the U.S. Additionally, in May 2020, the U.S. FDA approved atezolizumab in combination with bevacizumab for the treatment of patients suffering from advanced metastatic hepatocellular carcinoma. The approval and adoption of such targeted therapy agents are expected to drive market growth.

Asia Pacific is expected to expand at the highest CAGR during the forecast period owing to the increase in target disease prevalence. The increasing healthcare expenditure and insurance coverage in the region is further expected to aid market growth. Due to a lack of effective screening practices and access to healthcare in this region cancers are mostly diagnosed at advanced stages. This represents a key growth opportunity for the market.

Key Companies & Market Share Insights

新产品发布尤其是胎面组合tments are the key focus areas for companies in the advanced hepatocellular carcinoma market. For instance, in March 2020, the U.S. FDA granted accelerated approval to Ono Pharmaceutical’s OPDIVO (nivolumab) with Yervoy (ipilimumab) for the treatment of advanced hepatocellular carcinoma. Another such combination therapy approved in the same year is atezolizumab in combination with bevacizumab. Some of the key players in the global liver metastases treatment market include:

• F. Hoffmann-La Roche Ltd.

• AstraZeneca

• Eli Lilly and Company

• Bayer AG

• Ono Pharmaceutical

• Pfizer, Inc.

• Bristol-Myers Squibb Company

• Cadila Pharmaceuticals Ltd.

Liver Metastases Treatment Market Report Scope

Report Attribute	Details
Market size value in 2023	USD 1.41 billion
Revenue forecast in 2030	USD 2.31 billion
Growth Rate	CAGR of 7.2% from 2023 to 2030
Base year for estimation	2022
Historical data	2018 - 2021
Forecast period	2023 - 2030
Quantitative units	Revenue in USD million/billion and CAGR from 2023 to 2030
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered	Treatment type, primary cancer, distribution channel, region
Regional scope	North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country scope	U.S.; Canada; U.K.; Germany; France; Spain; Italy; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait,
Key companies profiled	F. Hoffmann-La Roche Ltd.; AstraZeneca; Bayer AG; Eli Lilly and Company; Ono Pharmaceutical; Pfizer, Inc.; Bristol-Myers Squibb Company; Cadila Pharmaceuticals Ltd.
Customization scope	Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs.Explore purchase options

GlobalLiver Metastases Treatment MarketSegmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segment from 2018 to 2030. For this study, Grand View Research has segmented the global liver metastases treatment market report on the basis of treatment type, primary cancer, distribution channel, and region:

• Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Chemotherapy

  • Targeted Therapy

  • Immunotherapy

• Primary Cancer Outlook (Revenue, USD Million, 2018 - 2030)

  • Colorectal Cancer

  • Breast Cancer

• 分销渠道前景(收入,百万美元, 2018 - 2030)

  • Hospital Pharmacies

  • Specialty Pharmacies

• Regional Outlook (Revenue, USD Million; 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

    • Rest of Europe

  • Asia Pacific

    • China

    • India

    • Japan

    • Australia

    • South Korea

    • Thailand

    • Rest of APAC

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Rest of LATAM

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

    • Rest of MEA